Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for … Read more
Cardiol Therapeutics Inc Class A (CRDL) - Total Assets
Latest total assets as of September 2025: $12.95 Million USD
Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) holds total assets worth $12.95 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cardiol Therapeutics Inc Class A - Total Assets Trend (2017–2024)
This chart illustrates how Cardiol Therapeutics Inc Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cardiol Therapeutics Inc Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Cardiol Therapeutics Inc Class A's total assets of $12.95 Million consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.0% |
| Accounts Receivable | $361.62K | 1.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Cardiol Therapeutics Inc Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cardiol Therapeutics Inc Class A's current assets represent 99.4% of total assets in 2024, an increase from 77.2% in 2017.
- Cash Position: Cash and equivalents constituted 96.0% of total assets in 2024, up from 73.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 22.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.1% of total assets.
Cardiol Therapeutics Inc Class A Competitors by Total Assets
Key competitors of Cardiol Therapeutics Inc Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp Preferred
KO:000105
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma
KO:000220
|
Korea | ₩202.42 Billion |
|
Ildong Holdings Co Ltd
KO:000230
|
Korea | ₩813.62 Billion |
Cardiol Therapeutics Inc Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cardiol Therapeutics Inc Class A generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cardiol Therapeutics Inc Class A is currently not profitable relative to its asset base.
Cardiol Therapeutics Inc Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.89 | 2.49 | 5.94 |
| Quick Ratio | 3.89 | 2.49 | 5.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.52 Million | $ 10.33 Million | $ 12.43 Million |
Cardiol Therapeutics Inc Class A - Advanced Valuation Insights
This section examines the relationship between Cardiol Therapeutics Inc Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.68 |
| Latest Market Cap to Assets Ratio | 2.51 |
| Asset Growth Rate (YoY) | -13.2% |
| Total Assets | $31.86 Million |
| Market Capitalization | $79.85 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cardiol Therapeutics Inc Class A's assets at a significant premium ( 2.51x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cardiol Therapeutics Inc Class A's assets decreased by 13.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cardiol Therapeutics Inc Class A (2017–2024)
The table below shows the annual total assets of Cardiol Therapeutics Inc Class A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $31.86 Million | -13.18% |
| 2023-12-31 | $36.70 Million | -19.80% |
| 2022-12-31 | $45.76 Million | -47.93% |
| 2021-12-31 | $87.88 Million | +452.92% |
| 2020-12-31 | $15.89 Million | +2.52% |
| 2019-12-31 | $15.50 Million | -37.20% |
| 2018-12-31 | $24.68 Million | +666.45% |
| 2017-12-31 | $3.22 Million | -- |